Workflow
科源制药:发行股份购买资产交易通过市场监管总局反垄断审查

Group 1 - The company, Koyuan Pharmaceutical, plans to acquire 99.42% equity of Shandong Hongjitang Pharmaceutical Group through a share issuance and raise matching funds [1] - The transaction requires approval from the State Administration for Market Regulation and has received a decision not to conduct further antitrust review [1] - The acquisition still needs to pass the Shenzhen Stock Exchange review and be registered with the China Securities Regulatory Commission [1]